

---

# PerKit™ Antibody PBD Dimer Conjugation Kit with Val-Ala Linker (CM11439.01x1 and CM11439.01x3) User Reference Guide

## Contents

Important Notes & Contact Information .....	2
Kit Components.....	3
Safety Information .....	4
Labeling Chemistry.....	4
Support .....	5
Protocol.....	6
1. Lab Instrumentation Needed.....	6
2. Prepare Site and PBD Dimer for Labeling Experiment.....	6
3. Preparation of Antibody Samples for Conjugation.....	7
4. Thiolation of Antibody (Step 1 in Scheme 1) .....	8
5. Purification to Remove Excess Reagent A .....	8
6. PBD Dimer Labeling (Step 2 in Scheme 1).....	9
7. Purification of Conjugate .....	10
Other Considerations.....	12
1. Concentration Determination for Antibody (Unlabeled).....	12
2. Concentration Determination for Conjugate.....	12
3. MW Calculation for Conjugate.....	13
4. Drug-to-Antibody Ratio (DAR or DPR) and Characterization by UV and MS .....	13
5. Characterization of Conjugates by HIC HPLC.....	13
6. Characterization of Conjugates by SEC HPLC.....	13
7. ADC Stabilizing Buffer .....	14
8. Recommended Storage Conditions .....	14
9. Sample Submission for HPLC Analysis .....	14
Appendix: Examples of Antibody- or Protein-PBD Dimer Conjugates .....	15



CellMosaic, Inc.  
10A Roessler Road  
Woburn, MA 01801  
USA

Phone: 781-463-0002  
Fax: 781-998-4694  
Email: [info@cellmosaic.com](mailto:info@cellmosaic.com)  
Website: [www.cellmosaic.com](http://www.cellmosaic.com)

---

## Important Notes & Contact Information

### READ BEFORE USING ANY RESOURCES PROVIDED HEREIN

The information and methods included in this document are provided for information purposes only. CellMosaic provides no warranty regarding performance or suitability for the purpose described. The performance of this kit during labeling may be affected by various factors, including, but not limited to, the purity and complexity of the starting materials, differences in preparation techniques, operator proficiency, and environmental conditions.

Sample data if provided, is provided solely for illustrative purposes and as examples of a small dataset used to verify kit performance within the CellMosaic laboratory. Information regarding the chemicals and reagents used in the kit is included where necessary.

### For Research Use Only. Not for Use in Diagnostic Procedures.

The information in this document is subject to change without notice. CellMosaic assumes no responsibility for any errors or omissions that may appear in this document. Under no circumstances shall CellMosaic be liable, whether in contract, tort, warranty, or under any statute or on other legal theory, for special, incidental, indirect, punitive, multiple, or consequential damages related to or arising from this document, including but not limited to the use of this product thereof.

### NOTICE TO PURCHASER: LIMITED LICENSE


Purchasing this product grants a limited, non-transferable license to use it solely for the purchaser's research activities to practice the labeling methods using the reagents. The license granted herein is personal to the original purchaser and may not be transferred to any other party outside the purchaser's company. No other right or license is conveyed or granted either expressly, by implication or by estoppel, to resell or repackage this product. Further information can be obtained by contacting:

Director of Licensing  
c/o CellMosaic, Inc.  
10-A Roessler Road, Woburn, MA 01801.  
Phone: 781-463-0002  
Fax: 781-998-4694  
E-mail: [info@cellmosaic.com](mailto:info@cellmosaic.com)

## Kit Components

Pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) are a class of antitumor antibiotics that were discovered in the 1960s. The first PBD, anthramycin, was isolated from the cultures of *Streptomyces*. PBDs are sequence-selective DNA minor-groove binding agents that inhibit nucleic acid synthesis. PBD dimers, with two PBD units linked via their C8 positions, are more potent DNA alkylating agents than monomers and have been used by several companies to develop antibody-drug conjugates. Examples include Rovalpituzumab tesirine (AbbVie/Stemcentrx), Vadastuximab talirine (Seattle Genetics), Camidanlumab tesirine, and Loncastuximab tesirine (ADC Therapeutics).

This kit provides materials to conjugate 100 µg (micrograms) of an antibody (IgG) (CM11439.01x1) or up to three separate antibody samples (CM11439.01x3) with the talirine (SGD-1910) PBD dimer using a valine-alanine linker.

 Upon receipt, please remove **Box 1** and store in a freezer at or below -20°C. Store **Box 2** in a refrigerator at 2-8°C.

	Name	Part #	Quantity (CM11413x1)	Quantity (CM11413x3)	Storage condition
Box 1	Mc-Val-Ala-PBD Dimer ( <b>red label</b> )	CM11030.01	1 unit	3 units	-20°C, dry
	Reagent A ( <b>cyan label</b> )	CM12101	1 unit	3 units	
	Reagent B solution ( <b>yellow label</b> )	CM12004.1	1 unit	3 units	
Box 2	Solution A ( <b>green label</b> )	CM01003	2 mL	6 mL	2-8°C
	Buffer A ( <b>orange label</b> )	CM02001	4 mL	12 mL	
	Buffer B ( <b>indigo label</b> )	CM02005	4 mL	12 mL	
	Storage Buffer (1 x PBS buffer) ( <b>grey label</b> )	CM02013	5 mL	20 mL	
	ADC Stabilizing PBS buffer (5x) ( <b>pink label</b> )	CM02022	0.5 mL	1.5 mL	
	Centrifugal Filter Devices	CM03CD050A	3	9	
	Collection Tubes for Filter	CM03CT0	6	18	
	Desalting Spin Column	CM03SG50	2	6	
	Collection Tubes for Spin Column	CM03CT9	2	6	
	0.5 mL Eppendorf Tubes	CM03CT7	2	6	
	1.5 mL Centrifuge Tubes	CM03CT2	2	6	
	Hazardous Waste Bag(s)	CM03HZ1	1	3	
User Material	Antibody	N/A	NOT PROVIDED (User Supplied Material): Antibody (IgG): <b>100 µg</b> per reaction		


**Drug-to-Antibody Ratio (DAR):** The protocol is optimized for IgG (150 kDa) to achieve an average DAR of 2–4. For other antibodies, the DAR may vary from 1–4, depending on the molecular weight of the antibody.

## Safety Information

Warning: some of the chemicals used in this kit may be hazardous and can cause injury or illness. Please read and understand the Safety Data Sheets (SDS) available at [CellMosaic.com](http://CellMosaic.com) before storing, handling, or using any of these materials.

## Labeling Chemistry


The kit is designed to label any antibody with PBD dimer using a dipeptide (Val-Ala) linker. The user supplies the antibody. Using the kit components, the user first converts the antibody into a thiol-protein through surface amine labeling, followed by reaction with maleimide-activated PBD dimer to generate antibody- or protein-PBD dimer conjugates. The product is then purified to remove any unreacted drug.



Key features of this conjugation kit:

- Simple and efficient labeling of antibody with PBD dimer, minimizing toxin exposure.
- Features an enzymatic dipeptide (Val-Ala) linker.
- Fast preparation: 6 hours total, with less than 2 hours of hands-on time.
- Includes all necessary reagents and supplies for preparation and purification.
- Post-conjugation services available at CellMosaic® for analysis and drug loading determination.

#### Drug Information:



- **Name:** Mc-Val-Ala-PBD Dimer (Talirine, SGD-1910)
- **CAS number:** 1342820-51-2
- **Chemical formula:** C<sub>60</sub>H<sub>64</sub>N<sub>8</sub>O<sub>12</sub>
- **MW:** 1089.2
- **Mechanism of action:** Sequence-selective DNA minor-groove binding agents, inhibition of nucleic acid synthesis
- **Activities:** Antitumor

#### Requirement for antibody:

1. Preferably > 90% pure by gel electrophoresis
2. Total amount: 0.667 nmol antibody content (100 µg IgG) as measured by UV. *Note:* the accuracy of your antibody measurement is the single most important factor in obtaining an optimized DAR or DPR of 2–4. Please refer to the “Other Considerations” section in this manual for instructions on measuring the antibody amount.


## Support


A customer can request a recommendation for conjugation if the MW of their antibody is not ~150KDa or if they need to label less than 0.667 nmol of antibody.

CellMosaic provides additional accessory tools, such as buffers, standards, and reagents for antibody-drug conjugate (ADC) research. The company also offers fee-based support services to customers who need assistance with final conjugate analysis by HPLC and drug loading determination.

If an ADC cannot be synthesized using classical linkers due to drug hydrophobicity, or if ADC efficacy is compromised by drug loading, customers can explore CellMosaic’s proprietary [hydrophilic and water-soluble AqT<sup>®</sup> Linked Drugs](#) for the development of next generation ADCs.

## Protocol

 Cap and briefly spin the tubes before opening



**Scheme 1.** Schematic workflow diagram for preparing Antibody-PBD dimer conjugates with Val-Ala linker, starting with 0.667 nmol of antibody (100 µg of IgG).

### 1. Lab Instrumentation Needed

- Vortex mixer, centrifuge (preferably refrigerated, 14,000 g capable), mini-centrifuge
- Pipettes and tips
- Timer
- Incubator or shaker set at 25°C and at RT
- Chemical hood
- Support stand, lab frame, or any support rod for desalting column
- Flask
- Personal protection equipment (lab coat, safety glasses, and chemical resistant nitrile gloves)

### 2. Prepare Site and PBD Dimer for Labeling Experiment

PBD dimer is highly hydrophobic, and antibody-drug conjugates with PBD dimer tend to aggregate and precipitate out of solution. Therefore, it is recommended to perform the labeling experiment just a few days before your subsequent experiments.

Always use personal protection equipment when handling PBD dimer. Ensure you are working in a clean space inside a chemical fume hood.

**A1.** Remove **Box 1** containing **PBD dimer** (red label), **Reagent A** (cyan label), and **Reagent B** solution (yellow label) from the -20°C freezer and allow it to warm to room temperature before opening the bag.

**A2.** Remove **Box 2** from the refrigerator. Place the hazardous waste bag inside the chemical hood for solid waste disposal and bring the remaining items to the lab bench.

**A3.** Check if the frozen liquid inside the **PBD dimer** tube has thawed. Briefly mix and spin the centrifuge tube containing PBD dimer. Place the PBD dimer tube in a tube holder inside the chemical hood and wait until the antibody is ready for conjugation.

**Tip for Opening Centrifuge Tubes After Mixing:** Always spin the tubes briefly to ensure no liquid remains in the cap before opening.

**A4.** Set incubator or shaker temperature to 25°C.

### 3. Preparation of Antibody Samples for Conjugation

Items needed: Filter Devices (CM03CD030A), Collection Tubes (CM03CT0), Buffer A (CM02001, Orange label), 1.5 mL Centrifuge Tube (CM03CT2), Clean Centrifuge Tubes (not provided in the kit).

The total amount of antibody (IgG with a MW of 150KDa) used for the conjugation is 0.1 mg (100 microgram) per reaction (protein content as measured by UV).

**B1.** Insert the Filter Device into one of the provided collection tubes (micro-centrifuge tube with the cap attached). Follow the appropriate step based on the condition of your antibody.

- ✓ **Lyophilized antibody:** Dissolve the antibody in 500 µL of deionized water and transfer the entire contents to the Filter Device.
- ✓ **Antibody in < 500 µL buffer:** Transfer the antibody sample directly to the Filter Device, then add Buffer A to bring the total volume to 500 µL. Cap the device.
- ✓ **Antibody in 500-1000 µL buffer:** Split the sample between two Filter Devices, adding the antibody to each device. Add Buffer A to bring the volume in each device to 500 µL and cap them.
- ✓ **Antibody in >1000 µL buffer:** Transfer up to 500 µL of the sample into two Filter Devices. Cap the devices and repeat **Steps B1-B4** until the entire antibody sample has been transferred. For the final refill (**Step B5**), add Buffer A to bring the total volume to 500 µL in each device.

**B2.** Place the capped Filter Device into the centrifuge rotor, ensuring the cap strap is aligned toward the center of the rotor. Counterbalance with a similar device.

**B3.** Spin the Filter Device at 14,000 x g for 8 minutes (preferably cooled at 4°C) to concentrate the sample to < **100 µL** (Spin time may vary; typically, a 500 µL sample will concentrate to ~40µL after 8 to 20 minutes of spinning. The typical time for an Eppendorf 5417R is 8 minutes).

**B4.** Remove the device from the centrifuge and separate the Filter Device from the collection tube. Transfer the filtrate from the collection tube to a clean centrifuge tube (not provided).

**Save the filtrate until all experiments are done.**

**B5.** Reinsert the Filter Device into the collection tube. Add 400-450 µL of Buffer A to bring the total volume to 500 µL. Place the capped Filter Device back into the centrifuge rotor, align the cap strap toward the center, and spin at 14,000 x g to concentrate the sample to < **100 µL**.

Remove the device, transfer the filtrate to a clean centrifuge tube (not provided). **Save the filtrate until all experiments are done.**

**B6.** Repeat **Step B5** two more times. For the last repeat, if you start with two **Filter Devices**, combine the samples into one **Filter Device** and spin at 14,000 x g to concentrate the solution to less than **20 µL**.

**B7.** Transfer the concentrated sample from the Filter Device to a 0.5 mL Eppendorf tube. Use a pipetman to measure the approximate volume of the concentrated sample. Calculate the volume of **Reducing Buffer** needed for rinsing the **Filter Device** in **Step B8**. After combining the concentrated sample from **Step B7** and the rinsing solution from **Step B8**, the total volume should be approximately **30-40 µL**.

**B8.** Add 10-20 µL of Buffer A to the Filter Device for rinsing. Stir gently with a pipet tip, then transfer the contents to the sample tube from **Step B7**.

**B9.** Vortex the combined antibody sample for 30 seconds and then spin down.

#### 4. Thiolation of Antibody (Step 1 in Scheme 1)

Items needed: Reagent A (CM12101, cyan label), Solution A (CM01003, green label), Antibody Solution from **Step B9**.

**C1.** Spin the centrifuge tube containing Reagent A (cyan label).

**C2.** Spin Solution A (green label) briefly before opening. Add **1.8 mL** of Solution A to the tube with Reagent A from **Step C1**. Vortex for 30 seconds to 1 minute to fully dissolve the reagent, then spin briefly.

**C3.** Transfer **2 µL** of Reagent A solution from **Step C2** to the centrifuge tube containing the antibody from **Step B9**. Discard any unused Reagent A as hazardous chemical waste **after completing all experiments**.

**C4.** Vortex the solution for 30 seconds, then spin briefly to ensure no liquid remains in the cap. Incubate the mixture at 25°C (room temperature, 20–27°C is acceptable) for exactly 1 hour.



Start Time: \_\_\_\_\_ End Time: \_\_\_\_\_

**Tip for mixing:** You can use a nutator, shaker, vortex, or incubator shaker for mixing. If using end-to-end nutating, ensure the tube from **step C4** is securely capped. If you don't have access to this equipment, you can let the tube sit on the bench and manually mix it by pipetting every 10 minutes.

#### 5. Purification to Remove Excess Reagent A



The following steps follow a similar filtration process as described in **Steps B1–B11**. These steps should be performed consecutively without interruption, as free thiols oxidize



quickly. Ensure that **Step A3** is completed before proceeding. Work quickly through **Steps E1–E2**.

Items needed: Filter Device (CM03CD050A), Collection Tubes (CM03CT0), Buffer B (CM02005, indigo label), Mc-Val-Ala-PBD Dimer (CM11030.1, red label), Reagent B Solution (CM12004.1, yellow label), 1.5 mL Centrifuge Tube (CM03CT2), Antibody Solution from **Step C4**.

**D1.** Transfer the thiol-modified antibody from **Step C4** directly into a new Filter Device. Rinse the centrifuge tube once with 200  $\mu$ L of Buffer B (indigo label) and transfer this solution to the Filter Device. Add Buffer B to bring the total volume to 500  $\mu$ L.

**D2.** Spin the Filter Device at 14,000  $\times g$  for 8 minutes to concentrate the sample to < 100  $\mu$ L.

**D3.** Transfer the filtrate from the collection tube to a clean centrifuge tube. **Save the filtrate until all experiments are done.**

**D4.** Reinsert the Filter Device into the collection tube. Add 400-450  $\mu$ L of Buffer B to bring the total volume to 500  $\mu$ L. Spin at 14,000  $\times g$  to concentrate to < 100  $\mu$ L. Transfer the filtrate to a clean centrifuge tube. **Save the filtrate until all experiments are done.**

**D5.** Repeat **Step D4** once. Spin the Filter Device at 14,000  $\times g$  to concentrate the solution to less than 20  $\mu$ L.

## 6. PBD Dimer Labeling (Step 2 in Scheme 1)

Items needed: PBD Dimer Solution from **step A3**, Hazardous Waste Bag (CM03HZ1), Antibody Solution from **step D5**.

**E1.** While wearing personal protection equipment, carefully open the tube containing PBD dimer from **Step A3**.

**E2.** Transfer the concentrated sample from the Filter Device from **Step D5** to the tube containing PBD dimer from **Step E1**. Use a pipetman to estimate the approximate volume of the concentrated sample. Calculate the volume of Buffer B needed for rinsing the Filter Device in **Step E3**. After combining the concentrated sample from **Step D5** and the rinsing solution from **Step E3** the total volume should be approximately 55  $\mu$ L

**E3.** Add 10-20  $\mu$ L of Buffer B to the Filter Device for rinsing. Stir gently with a pipet tip, then transfer the entire contents to the sample tube from **Step E2**

**E4.** Cap the tube and mix the solution at 25°C (room temperature, 20–27°C is acceptable) for 1 hour.

Work quickly



Start Time: \_\_\_\_\_ End Time: \_\_\_\_\_

**E5.** Spin the centrifuge tube containing Reagent B solution (Yellow label).

**E6.** Spin the PBD dimer-labeled antibody solution from **Step E4** before opening it. Add 1  $\mu$ L of Reagent B solution from **Step E5** to the tube. **Discard any unused Reagent B as hazardous chemical waste after completing all experiments.**

**E6.** Vortex the solution for 30 seconds, then spin it down. Mix the solution at 25°C (room temperature, 20–27°C is acceptable) for 30 minutes.



Start Time: \_\_\_\_\_ End Time: \_\_\_\_\_

**Time-saving tip:** While waiting for the reaction to complete, you can proceed to **Step F1** and begin equilibrating the column for purification.

## 7. Purification of Conjugate

Items needed: Desalting Spin Column (CM03SG50), Storage Buffer (1x PBS), ADC Stabilizing PBS Buffer (5x) (CM02022, pink label), Collection Tubes for Spin Column (CM03CT9), 1.5 mL Centrifuge Tube (CM03CT2), Hazardous Waste Bag (CM03HZ1), Antibody Solution from **Step E6**.

**F1.** Take out two desalting spin columns and remove the bottom red cap. Spin the columns for 1 minute at 750 x g before opening the top cap.

**F2.** Apply 400 µL of PBS buffer (grey label) to the top-center of the resin in each column. Allow the resin to swell at room temperature for 15 minutes.

**F3.** Spin the columns for 1 minute at 750 x g and discard the flow-through.



**F4.** Repeat **Steps F2–F3** once. Spin immediately after applying PBS, without wait, and discard the flow-through.

**F5.** Insert the spin columns into clean 1.5 mL collection tubes.

**F6.** Spin the PBD dimer-labeled antibody solution from **Step E6** to ensure no liquid remains in the cap before opening.

**F7.** Slowly apply up to 30 µL of the conjugate solution from **Step E3** to the top-center of the resin in each spin column, taking care not to disturb the resin bed (2 x 30 µL).


**F8.** Wash the tube with 40 µL of PBS buffer, then apply 20 µL of PBS buffer to the top-center of the resin in each spin column, bringing the total volume in each column to 50 µL. **Dispose of the centrifuge tube in the solid waste bag.**



The resin may slightly detach from the column to form, forming a pillar with an unbalanced resin bed due to centrifuge force. To prevent issues, ensure that both the sample and subsequent PBS buffer are applied slowly to the center of the resin bed, avoiding any runoff down the sides. Wait for the conjugate solution to fully enter the

resin before applying the PBS buffer. Be careful not to touch the resin bed with the pipette tip.

**F9.** Rotate and align the spin column so that the higher side of the resin bed is positioned against the outer wall of the centrifuge rotor, while lower side faces the center. Spin for 2 min at 750 x *g* to collect the fractions.



**F10.** Transfer and combine the fractions from the two collection tubes into the provided 1.5 mL centrifuge tube and cap it. **Dispose of the Desalting Spin Columns and Collection Tubes in the solid waste bag, then seal the bag. Follow local regulations for proper waste disposal.**

**F11.** Add 25  $\mu$ L of ADC Stabilizing PBS buffer (5x) to the antibody-PBD Dimer from **Step F10**. Aliquot and store the conjugate in a  $< -20^{\circ}\text{C}$  freezer or lyophilize to dryness.

**F12.** Determine the concentration and the estimated loading by UV/Vis spectrophotometry (see other considerations).

### Conjugate is Ready for Your Experiment

- **Specifications of your product:** A typical batch contains around 70–90% conjugated products, as determined by hydrophobic interaction chromatography (HIC) with an average of 2–4 drugs per antibody and is free of any unreacted drug. The approximate concentration of the conjugate is 2.67  $\mu\text{M}$  (0.4 mg/mL for IgG) assuming 50% recovery. You can determine the concentration and estimated the loading by UV/vis spectrophotometry (see Other Considerations).

## Other Considerations

### 1. Concentration Determination for Antibody (Unlabeled)

Accurately determining the antibody concentration is crucial for optimizing drug loading in this protocol. The simplest method is to measure absorbance at 280 nm, provided you know the extinction coefficient of your antibody. Otherwise, an antibody assay, such as BCA, can be used to determine the concentration.

If your antibody is in a buffer that does not absorb at 280 nm, you can measure the UV absorbance directly before starting the experiment.

$$\text{Concentration (M) of antibody or protein} = \frac{(A_{280})}{\epsilon \times L}$$

Where **L** is the UV cell path length (cm), and **ε** is the extinction coefficient of your antibody (cm<sup>-1</sup>M<sup>-1</sup>)

If your antibody is in a buffer that absorbs at 280 nm, determine the concentration after buffer exchange with Buffer B (**step B10**), assuming **95%** recovery of the antibody. Buffer A does not interfere with UV measurement at 280 nm. The total volume of **Buffer A** added in **Step B10** is estimated based on the initially calculated amount of **antibody**. Minor variations in volume will not significantly affect the conjugation process.

$$\text{Concentration (M) of Starting Protein} = \frac{(A_{280})}{\epsilon \times L \times 0.95}$$

After calculating the total amount of antibody, follow the calculations in **Steps B10, C3, D9, E2, E5, F5, F6, and F7** to ensure correct volumes are used in each step.

### 2. Concentration Determination for Conjugate

To determine the conjugate concentration, dilute your sample from **Step F7** with 1x PBS buffer.

Dilute ADC Stabilizing PBS buffer 5 times with 1xPBS and then dilute this PBS buffer in the same way as the conjugate to serve as a buffer control.

Measure the UV absorbance of the conjugate at 280 nm (A<sub>280</sub>) using a UV spectrometer and calculate the conjugate concentration using the following formula:

$$\text{Concentration (}\mu\text{M) of the dilute sample} = \frac{(A_{280}) * 1000000}{\epsilon \times L}$$

$$\text{Concentration (mg/mL) of the dilute sample} = \frac{(A_{280}) \times MW(\text{Conjugate})}{\epsilon \times L}$$

Where **L** is the UV cell path length (cm), and **ε** is the extinction coefficient of your antibody (cm<sup>-1</sup>M<sup>-1</sup>). If you are using a 1 cm UV cell, you may dilute the conjugate 2-4 times to obtain an accurate reading.

The contribution from the drugs at 280 nm is considered very small and is not taken into account here.

For a typical IgG with a molecule weight (MW) of 150,000, the molar extinction coefficient is 210,000 M<sup>-1</sup>cm<sup>-1</sup>.

### 3. MW Calculation for Conjugate

Calculation of the MW of the conjugate:

$$\text{MW(PDC)} = n \times 1227 + \text{MW (Antibody)}$$

Where  $n$  is the average molar ratio of PBD dimer per antibody. If the experimental DPR is unavailable, use 1.5 for antibody with MW of 20-60kDa, 2 for antibody with MW 60-100 kDa, 3 for antibody with MW  $\geq 100$  kDa.

### 4. Drug-to-Antibody Ratio (DAR or DPR) and Characterization by UV and MS

PBD dimers have a characteristic UV absorbance maximum at around 330 nm. The presence of a UV peak at 330 nm indicates drug loading. For drug loading determination, we strongly recommend sending your samples for intact mass spectrometry (MS) analysis using either MALDI-TOF MS or LC-MS. By comparing the intact MS spectra of the conjugate with those of the unlabeled antibody, you can calculate the average drug-to-antibody ratio (DAR) or drug-to-protein ratio (DPR). If you do not have access to an MS facility, please contact CellMosaic for analysis.

### 5. Characterization of Conjugates by HIC HPLC

For conjugate prepared via surface amine labeling of the antibody, hydrophobic interaction chromatography (HIC) HPLC can be used to determine whether labeling has occurred. However, due to the highly heterogeneous nature of surface amine labeling, antibodies or proteins with the same DAR or DPR may exhibit slight differences in hydrophobicity. For a typical HIC profile of PBD dimer conjugate, please refer to the Appendix.

CellMosaic offers an HIC buffer set ([Product #: CM02025](#)) that can be used with any HIC column. The CM02025 product sheet includes detailed information and methodology for running HIC HPLC analysis.

If you do not have access to an HPLC facility, you can send your sample to CellMosaic for analysis.

### 6. Characterization of Conjugates by SEC HPLC

PBD dimer with Val-Ala is highly hydrophobic. This kit is designed to minimize the aggregation and precipitation issues typically encountered with PBD dimer labeling. However, you may still notice some solid precipitate or conjugate aggregation during the reaction. The precipitates will be removed during purification. Depending on the properties of your antibody, recovery may range from 40-80%.

If you are concerned about aggregation, you can use size exclusion chromatography (SEC) to assess the extent of aggregation. SEC separates conjugates based on apparent molecular weight (MW) or size in aqueous solution. Larger MW conjugates elute earlier. By comparing the SEC profile of unlabeled antibody to that of the conjugate, you can estimate the level of aggregation in the conjugate.

CellMosaic offers two SEC standards ([Product #: CM92004](#) and [CM92005](#)) for use with any SEC column. The CM92004 product sheet provides all the necessary information and methodology for running an SEC HPLC analysis.

If you do not have access to an HPLC facility, you can send your sample to CellMosaic for analysis.

## 7. ADC Stabilizing Buffer

CellMosaic's proprietary ADC Stabilizing PBS buffer (5x) ([Product #: CM02022](#)) contains 5x PBS buffer and other stabilizers designed to prevent hydrophobic drugs from interacting with each other during storage, which can lead to conjugate precipitation. The Stabilizing Buffer also helps preserve the structure of the conjugate during lyophilization. This biocompatible buffer can be used directly for both *in vitro* and *in vivo* studies. For more information on stabilization buffers, please visit our website.

## 8. Recommended Storage Conditions

This antibody- or protein-PBD dimer conjugate with a traditional hydrophobic linker is not very stable due to aggregation and precipitation issues. The stability of your conjugate may vary depending on your antibody and should be assessed using HPLC or UV analysis. If you need to store the conjugates for a longer period, dilute your conjugate in Stabilization PBS buffer (5x) (included in this kit). Aliquot and store the conjugate in a < -20°C freezer or lyophilize to dryness. Avoid repeated freeze and thaw cycles.

## 9. Sample Submission for HPLC Analysis

If you are submitting samples to CellMosaic for SEC and HIC analysis, please follow these instructions:

- 1) Visit CellMosaic's HPLC analysis page (<https://www.cellmosaic.com/hplc-analysis/>), select SEC HPLC Analysis ([Product# AS0023](#)) and HIC HPLC Analysis ([Product#: AS0025](#)), choose the quantity (number of samples. Bulk discounts available for multiple samples), and submit your order. Alternatively, you can email [info@cellmosaic.com](mailto:info@cellmosaic.com) for a quote and to place the order.
- 2) Dilute your un-conjugated antibody in PBS buffer to a concentration of 1 mg/mL. Transfer 50 µL of the diluted solution into a 500 µL micro-centrifuge tube and label the vial properly.
- 3) Transfer 50 µL of conjugate (non-diluted solution) into a 500 µL micro-centrifuge tube and label the vial properly.
- 4) Ship your samples with a cold pack for overnight delivery.

## Appendix: Examples of Antibody- or Protein-PBD Dimer Conjugates

### Example: Mc-Val-Ala-PBD Dimer Conjugation with Monoclonal Human IgG1 Subtype Antibody

The ADC was prepared at CellMosaic following the DCM11439 User Manual (Rev. A) with some adjustments.

Mc-Val-Ala-PBD Dimer lot number(s): S576.S7.1126D

Scale of the reaction: 6.67 nmol (1.0 mg) Antibody

#### Specifications of the final conjugates:


Calculated DAR based on the HIC data: ~2.7 (Multiple DAR products)

Unreacted antibodies: 21.3%

ADC recovery: 75%

Aggregation: 12.3%

**Figure 1:** HIC HPLC analysis of monoclonal human IgG1 (Panel A), and purified Antibody-Val-Ala-PBD Dimer conjugates (Panel B).



**Figure 2:** SEC HPLC analysis of monoclonal human IgG1 (Panel C), and purified Antibody-Val-Ala-PBD Dimer conjugates (Panel D) at 280 and 330 nm. 330 nm absorbance is characteristic of PBD dimer.

